Manus Bio makes series A breakthrough


A recent article on Manus Bio  – 

The MIT spinout has raised $19.4m from unnamed backers, and the plant-based ingredient developer will use the cash to expand its production capacity.

Manus Bio, a US-based natural ingredient supplier spun out from Massachusetts Institute of Technology (MIT), has secured $19.4m in a series A round backed by unnamed new and existing investors. Byron Alsberg, partner at venture capital firm 415 Investments, has joined Manus Bio’s board of directors.


Read the article